Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Bolla

Showing results (1-10 of 158) with videos related to

Pageof 16
Sort By:
European Urology|August 7, 2013
Words of wisdom: Re: High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: results of a phase III randomized study [abstract 3]Michel Bolla
The Lancet. Oncology|October 17, 2016
24-gene predictor of response to postoperative irradiationMichel Bolla
The Lancet. Oncology|November 3, 2015
Hypofractionation for prostate cancer and PROsMichel Bolla
Nature Clinical Practice. Urology|February 14, 2006
Does adjuvant androgen suppression after radiotherapy for prostate cancer improve long-term outcomes?Michel Bolla
European Urology|February 26, 2008
Clinical stage T3 prostate cancer: the added value of three-dimensional conformal/intensity-modulated external-beam radiotherapyMichel Bolla
European Urology|October 14, 2015
Re: Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate ThemMichel Bolla
European Urology|September 28, 2011
Intermediate- and high-risk prostate cancer: a plea for high-dose, high-precision intensity-modulated radiotherapy with a modulated duration of androgen deprivation therapyMichel Bolla
European Urology|December 26, 2012
Adjuvant or immediate external irradiation after radical prostatectomy with pelvic lymph node dissection for high-risk prostate cancer: a multidisciplinary decisionMichel Bolla
European Urology|May 4, 2012
The moving landscape of locally advanced prostate cancer: combination of external irradiation and endocrine treatment and/or multimodal approachMichel Bolla
Nature Clinical Practice. Urology|June 26, 2008
What is the role of radiation dose escalation in the treatment of localized prostate cancer?Michel Bolla
Pageof 16

Showing results (1-10 of 158) with videos related to

Sort By:
Pageof 16
European Urology|August 7, 2013
Words of wisdom: Re: High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: results of a phase III randomized study [abstract 3]Michel Bolla
The Lancet. Oncology|October 17, 2016
24-gene predictor of response to postoperative irradiationMichel Bolla
The Lancet. Oncology|November 3, 2015
Hypofractionation for prostate cancer and PROsMichel Bolla
Nature Clinical Practice. Urology|February 14, 2006
Does adjuvant androgen suppression after radiotherapy for prostate cancer improve long-term outcomes?Michel Bolla
European Urology|February 26, 2008
Clinical stage T3 prostate cancer: the added value of three-dimensional conformal/intensity-modulated external-beam radiotherapyMichel Bolla
European Urology|October 14, 2015
Re: Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate ThemMichel Bolla
European Urology|September 28, 2011
Intermediate- and high-risk prostate cancer: a plea for high-dose, high-precision intensity-modulated radiotherapy with a modulated duration of androgen deprivation therapyMichel Bolla
European Urology|December 26, 2012
Adjuvant or immediate external irradiation after radical prostatectomy with pelvic lymph node dissection for high-risk prostate cancer: a multidisciplinary decisionMichel Bolla
European Urology|May 4, 2012
The moving landscape of locally advanced prostate cancer: combination of external irradiation and endocrine treatment and/or multimodal approachMichel Bolla
Nature Clinical Practice. Urology|June 26, 2008
What is the role of radiation dose escalation in the treatment of localized prostate cancer?Michel Bolla
Pageof 16